Mark Dorfman sold $211k of DRS
EVP, GC and Secretary at Leonardo DRS, Inc.. 4,659 shares at an average of $45.38, traded Apr 2, 2026, filed Apr 3, 2026.
Score components
- +15RoleOfficer
- +12Trade size$211k at market
- 0Share of holdings soldSold 9.9% of holdings
- +15Cluster3 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -14.3%, 3m -6.2%, 6m -20.9%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001849648-26-000006, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Apr 1, 2026 | AGrant or award Common Stock10b5-1 | +23,367 | $0.00 | $0 | 41,033 | Apr 3, 2026 |
| Apr 1, 2026 | FTax withholding Common Stock10b5-1 | -9,956 | $45.86 | $457k | 31,077 | Apr 3, 2026 |
| Apr 1, 2026 | AGrant or award Common Stock10b5-1 | +15,664 | $0.00 | $0 | 46,741 | Apr 3, 2026 |
| Apr 1, 2026 | FTax withholding Common Stock10b5-1 | -7,684 | $45.86 | $352k | 39,057 | Apr 3, 2026 |
| Apr 1, 2026 | MOption exercise Common Stock10b5-1 | +7,252 | $0.00 | $0 | 46,309 | Apr 3, 2026 |
| Apr 1, 2026 | FTax withholding Common Stock10b5-1 | -3,558 | $45.86 | $163k | 42,751 | Apr 3, 2026 |
| Apr 1, 2026 | MOption exercise Common Stock10b5-1 | +4,770 | $0.00 | $0 | 47,521 | Apr 3, 2026 |
| Apr 1, 2026 | FTax withholding Common Stock10b5-1 | -2,340 | $45.86 | $107k | 45,181 | Apr 3, 2026 |
| Apr 1, 2026 | MOption exercise Common Stock10b5-1 | +3,448 | $0.00 | $0 | 48,629 | Apr 3, 2026 |
| Apr 1, 2026 | FTax withholding Common Stock10b5-1 | -1,692 | $45.86 | $78k | 46,937 | Apr 3, 2026 |
| Apr 2, 2026 | SOpen-market sale Common Stock10b5-1 | -4,659 | $45.38 | $211k | 42,278 | Apr 3, 2026 |
| Apr 1, 2026 | MOption exercise Restricted Stock Unitderivative10b5-1 | -7,252 | $0.00 | $0 | 0 | Apr 3, 2026 |
| Apr 1, 2026 | MOption exercise Restricted Stock Unitderivative10b5-1 | -4,770 | $0.00 | $0 | 4,772 | Apr 3, 2026 |
| Apr 1, 2026 | MOption exercise Restricted Stock Unitderivative10b5-1 | -3,448 | $0.00 | $0 | 6,896 | Apr 3, 2026 |
Related signals
Other insiders at Leonardo DRS, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 22Weak | Leonardo DRS, Inc. | Mark Dorfman EVP, GC and Secretary | $277k 7,471 shares | -20% | |
| 42Moderate | Leonardo DRS, Inc. | Michael Dippold EVP and CFO | $755k 20,317 shares | -37% | |
| 12Weak | Leonardo DRS, Inc. | Jason Rinsky EVP Chief Tax and Treasury | $177k 3,864 shares | -14% | |
| 12Weak | Leonardo DRS, Inc. | Jason Rinsky EVP Chief Tax and Treasury | $175k 3,865 shares | -12% | |
| 50Moderate | Leonardo DRS, Inc. | John Baylouny President and CEO | $1.7M 36,471 shares | -23% | |
| 23Weak | Leonardo DRS, Inc. | Sally Wallace EVP, Chief Operating Officer | $65k 1,300 shares | -2% | |
| 38Weak | Leonardo DRS, Inc. | Michael Dippold EVP and CFO | $387k 8,318 shares | -13% | |
| 28Weak | Leonardo DRS, Inc. | Mark Dorfman EVP, GC and Secretary | $253k 5,536 shares | -13% | |
| 27Weak | Leonardo DRS, Inc. | Jason Rinsky EVP Chief Tax and Treasury | $181k 3,865 shares | -11% | |
| 68Notable | Leonardo DRS, Inc. | Pamela Morrow SVP and Controller | $521k 11,545 shares | -52% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.